CoChat

Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial

Open access
Vitanza, Nicholas A., Ronsley, Rebecca, Choe, Michelle, Seidel, Kristy, Huang, Wenjun, Rawlings-Rhea, Stephanie D., Beam, Madison, Steinmetzer, Leonel, Wilson, Ashley L., Brown, Christopher, Beebe, Adam, Lindgren, Catherine, Gustafson, Joshua A., Wein, Amy, Holtzclaw, Susan, Hoeppner, Corrine, Goldstein, Hannah E., Browd, Samuel R., Hauptman, Jason S., Lee, Amy, Ojemann, Jeffrey G., Crotty, Erin E., Leary, Sarah E. S., Perez, Francisco A., Wright, Jason N., Alonso, Marta M., Dun, Matthew D., Foster, Jessica B., Hurst, Diana, Kong, Ada, Thomsen, Alison, Orentas, Rimas J., Albert, Catherine M., Pinto, Navin, Annesley, Colleen, Gardner, Rebecca A., Ho, On, Pattabhi, Sowmya, Gust, Juliane, Wendler, Jason P., Park, Julie R., Jensen, Michael C. · 2025 · Nature Medicine
Cited by 175

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Diffuse intrinsic pontine glioma (DIPG) is a fatal central nervous system (CNS) tumor that confers a median survival of 11 months. As B7-H3 is expressed on pediatric CNS tumors, we conducted BrainChild-03, a single-center, dose-escalation phase 1 clinical trial of repetitive intracerebroventricular (ICV) dosing of B7-H3-targeting chimeric antigen receptor T cells (B7-H3 CAR T cells) for children with recurrent or refractory CNS tumors and DIPG. Here we report results from Arm C, restricted to patients with DIPG. The primary objectives were to assess feasibility and tolerability, which were both met. Secondary objectives included assessments of CAR T cell distribution and survival. A total of 23 patients with DIPG enrolled, and 21 were treated with repeated doses of ICV B7-H3 CAR T cells using intra-patient dose-escalation regimens without previous lymphodepletion. Concurrent tumor-directed therapy, including re-irradiation, was not allowed while on protocol therapy. We delivered a total of 253 ICV doses and established the highest planned dose regimen, DR4, which escalated up to 10 × 10 7 cells per dose, as the maximally tolerated dose regimen. Common adverse events included headache, fatigue and fever. There was one dose-limiting toxicity (intratumoral hemorrhage) during DR2. For all treated patients ( n = 21), the median survival from their initial CAR T cell infusion was 10.7 months and the median survival from diagnosis was 19.8 months with 3 patients still alive at 44, 45 and 52 months from diagnosis. Ultimately, this completed first-in-human trial shows that repetitive ICV dosing of B7-H3 CAR T cells in pediatric and young adult patients with DIPG is tolerable, including multiyear repeated dosing, and may have clinical efficacy that warrants further investigation on a multisite phase 2 trial. ClinicalTrials.gov registration: NCT04185038 .

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-024-03451-3

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Metadata

Authors
Vitanza, N. A., Ronsley, R., Choe, M., Seidel, K., Huang, W., Rawlings-Rhea, S. D., Beam, M., Steinmetzer, L., Wilson, A. L., Brown, C., Beebe, A., Lindgren, C., Gustafson, J. A., Wein, A., Holtzclaw, S., Hoeppner, C., Goldstein, H. E., Browd, S. R., Hauptman, J. S., Lee, A., Ojemann, J. G., Crotty, E. E., Leary, S. E. S., Perez, F. A., Wright, J. N., Alonso, M. M., Dun, M. D., Foster, J. B., Hurst, D., Kong, A., Thomsen, A., Orentas, R. J., Albert, C. M., Pinto, N., Annesley, C., Gardner, R. A., Ho, O., Pattabhi, S., Gust, J., Wendler, J. P., Park, J. R., & Jensen, M. C.
Venue
Nature Medicine
Published
2025-01-07
Volume
31
Issue
3
Pages
861-868
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4406150643
Cited by
175
References
3
FWCI
63.81
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial. https://app.cochat.ai/papers/10.1038/s41591-024-03451-3
The paper
Vitanza, N. A., Ronsley, R., Choe, M., Seidel, K., Huang, W., Rawlings-Rhea, S. D., Beam, M., Steinmetzer, L., Wilson, A. L., Brown, C., Beebe, A., Lindgren, C., Gustafson, J. A., Wein, A., Holtzclaw, S., Hoeppner, C., Goldstein, H. E., Browd, S. R., Hauptman, J. S., . . . Jensen, M. C. (2025). Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial. Nature Medicine. https://doi.org/10.1038/s41591-024-03451-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.